Manual screening for gastric carcinoma and mucosal pathogens, like Helicobacter pylori, is a highly demanding and time-consuming task, prone to diagnostic fatigue[1]. Isolated, subtle single tumor foci and low bacterial density are inherently subject to interobserver variability under heavy workload pressure. Such fragmented cell patterns can easily be overlooked, especially in small biopsy samples. It is a high-stakes review process, as a minor oversight in early detection can significantly alter staging, patient management, and treatment outcomes[2, 3].
In modern day digital pathology, artificial intelligence (AI)-powered image analysis is stepping into the picture with possibilities that extend beyond human limits and boundaries. The CE-IVD marked Aiforia® Gastric Cancer AI solution is designed to specifically support pathologists and address the high-workload, high-stakes review process for gastric biopsies. By automatically analyzing digitized whole-slide images, flagging suspicious tissue regions, and applying consistent diagnostic criteria, the tireless AI assistant helps streamline the workflow, from a worklist triage to sign-off on pre-filled reports.
Gastric tissue samples often present complex, significant screening obstacles that heavily burden pathology laboratories. Diffuse, poorly cohesive carcinoma cells frequently infiltrate surrounding tissue without forming cohesive masses, easily blending into background inflammation or mimicking reactive stromal cells within the lamina propria.[4]. Consequently, identifying such small tumor foci from background requires meticulous manual scanning across large whole slide images, often with high-magnification (40x)[3, 5]. High daily biopsy volumes and dense slide tracks elevate the risk of diagnostic oversight, particularly during the late-afternoon sign-outs when cognitive fatigue peaks.
Furthermore, inter-pathologist diagnostic consistency across a department often varies when evaluating borderline cases, such as distinguishing low-grade dysplasia from reactive atypia. The interpretation relies heavily on subspecialty experience, further challenged by cognitive load. Together, these factors create a critical diagnostic bottleneck where high slide volume, visual ambiguity, and human fatigue intersect. Clinically speaking, it reinforces the need for automated, objective decision-support tools.
Diffuse-type gastric carcinomas present a major diagnostic challenge because poorly cohesive tumor cells blend into surrounding stroma and inflammation. The Aiforia® Gastric Cancer AI solution is designed to help pathologists catch the scattered cell clusters that are easily missed during manual screening.
To directly address the high volumes, screening fatigue, and diagnostic ambiguity in gastric histopathology, the Foundation Engine-based Aiforia® Gastric Cancer AI model acts as an observant decision-support assistant with relentless analytical grasp. By automatically pre-screening digitized whole-slide images for the pathologist, the AI model flags suspicious microscopic neoplastic foci, thereby providing the medical specialist with a starting point and enabling them to hit the ground running.
Rather than relying on non-specific heatmaps, the Aiforia® Gastric Cancer AI solution delivers precise, cell-level visual overlays and quantifications, allowing pathologists to immediately review and evaluate tumor boundaries, surface areas, and lesion density at any magnification, without tedious manual area calculations. Even the most subtle foci and patterns that are easily overlooked, especially in small, fragmented biopsy pieces or in tissue sections masked by dense background inflammation, are analyzed down to cell-level detail by the algorithm.
In clinical performance evaluation studies on digitized H&E-stained human gastric biopsies, Aiforia® Gastric Cancer demonstrated high diagnostic precision, with a sensitivity of 96.8% and a specificity of 99.8%. Statistical agreement with expert ground truth reached a Cohen's Kappa score of 0.991, representing near-perfect alignment. Furthermore, integrating the AI tool into slide reading resulted in up to 48% reduction in case reporting time.[6] In clinical practice, the pathologist maintains full control over reviewing AI annotations before signing off on the patient case report.
Navigating the diagnostic complexities of gastric pathology requires tools that enhance diagnostic sensitivity without compromising clinical workflow speed. AI assistance helps ensure that even subtle, poorly cohesive malignant foci and sparse pathogens are identified efficiently and reliably. By combining automated case triaging, cell-level tumor flagging, and quantitative metrics with expert clinical judgment, diagnostic accuracy improves and turnaround times are reduced.
The Aiforia® Gastric Cancer forms part of the comprehensive Aiforia® Gastric Suite, an end-to-end clinical solution designed to streamline gastrointestinal diagnostics from initial screening to final report sign-off.
Discover how the complete suite supports pathologists and transforms GI laboratory workflows by booking a demo with our experts: request a demo.
References:
[1] Khatab, Z., Hanna, K., Rofaeil, A., Wang, C., Maung, R., & Yousef, G. M. (2024). Pathologist workload, burnout, and wellness: Connecting the dots. Critical Reviews in Clinical Laboratory Sciences, 61(4), 254–274. https://doi.org/10.1080/10408363.2023.2285284
[2] Niazi, M. K. K., Parwani, A. V., & Gurcan, M. N. (2019). Digital pathology and artificial intelligence. The Lancet Oncology, 20(5), e253–e261. https://doi.org/10.1016/S1470-2045(19)30154-8
[3] Nagaraju, G. P., Sandhya, T., Srilatha, M., Ganji, S. P., Saddala, M. S., & El-Rayes, B. F. (2025). Artificial intelligence in gastrointestinal cancers: Diagnostic, prognostic, and surgical strategies. Cancer Letters, 612, 217461. https://doi.org/10.1016/j.canlet.2025.217461
[4] Iyer, P., Moslim, M., Farma, J. M., & Denlinger, C. S. (2020). Diffuse gastric cancer: Histologic, molecular, and genetic basis of disease. Translational Gastroenterology and Hepatology, 5, 52. https://doi.org/10.21037/tgh.2020.01.02
[5] Go, H. (2022). Digital pathology and artificial intelligence applications in pathology. Brain Tumor Research and Treatment, 10(2), 76–82. https://doi.org/10.14791/btrt.2021.0032
[6] Aiforia Technologies, Clinical performance evaluation study for Aiforia® Gastric Cancer (technical file).